Erschienen in:
01.02.2014
Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage
verfasst von:
Jennifer L. Aron, Robert Gosselin, Stephan Moll, Charles F. Arkin, Simon Mantha
Erschienen in:
Journal of Thrombosis and Thrombolysis
|
Ausgabe 2/2014
Einloggen, um Zugang zu erhalten
Excerpt
The direct thrombin inhibitor dabigatran has been approved for clinical use in many countries for the prevention of stroke and systemic embolism in patients with atrial fibrillation. However, there is no known reversal agent or proven management strategy, and the best laboratory marker of hemostatic impairment to use in guiding treatment is unknown. We report the case of a patient on dabigatran for atrial fibrillation presenting with spontaneous intracranial hemorrhage (ICH). Recombinant activated factor VII (rFVIIa) was administered, with thrombin generation (TG) and thromboelastography (TEG) testing performed before and after injection. …